Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.52 USD | +0.13% | -0.91% | -6.86% |
17/05 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
02/04 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.86% | 1.83Cr | |
+36.70% | 73TCr | |
-6.98% | 35TCr | |
+16.13% | 33TCr | |
+0.10% | 28TCr | |
+13.74% | 24TCr | |
+7.39% | 21TCr | |
-6.22% | 20TCr | |
+4.39% | 16TCr | |
-1.25% | 16TCr |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Transcript : Kala Pharmaceuticals, Inc. Presents at BofA Securities 2021 Virtual Health Care Conference, May-13-2021 04